{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:52:18Z","timestamp":1778043138600,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":97,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.ctarc.2020.100174","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T12:26:51Z","timestamp":1587385611000},"page":"100174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS"],"prefix":"10.1016","volume":"23","author":[{"given":"Jonathan W.","family":"Riess","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine S.","family":"Jahchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Millie","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zach Koontz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Schatzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Sage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"28","key":"10.1016\/j.ctarc.2020.100174_bib0001","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100174_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cllc.2013.12.010","article-title":"Left behind? Drug discovery in extensive-stage small-cell lung cancer","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"23","key":"10.1016\/j.ctarc.2020.100174_bib0003","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100174_bib0004","first-page":"482","article-title":"Evolving role of irinotecan in small-cell lung cancer","volume":"1","author":"Spigel","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100174_bib0005","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1200\/JCO.1997.15.5.2090","volume":"15","author":"Ardizzoni","year":"1997","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctarc.2020.100174_bib0006","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2020.100174_bib0007","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","article-title":"The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas","volume":"39","author":"Strosberg","year":"2010","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100174_bib0008","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J Health Econ"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100174_bib0009","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"25","key":"10.1016\/j.ctarc.2020.100174_bib0010","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2007.11.8109","article-title":"Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01","volume":"25","author":"Pujol","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2020.100174_bib0011","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1038\/bcj.2015.25","article-title":"Acute promyelocytic leukemia: where did we start, where are we now, and the future","volume":"5","author":"Coombs","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.ctarc.2020.100174_bib0012","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/2159-8290.CD-13-0183","article-title":"A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors","volume":"3","author":"Jahchan","year":"2013","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100174_bib0013","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/0008-5472.CAN-17-0123","article-title":"Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer","volume":"78","author":"McClinch","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctarc.2020.100174_bib0014","first-page":"33","article-title":"Relationship between anti-depressant use and lung cancer survival","volume":"10","author":"Zingone","year":"2017","journal-title":"Cancer Treat Res Commun"}],"updated-by":[{"DOI":"10.1016\/j.ctarc.2022.100608","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220300113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:19:11Z","timestamp":1762841951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220300113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":14,"alternative-id":["S2468294220300113"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100174","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100174"}}